Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2020-07-14 Major Shareholding Noti…
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 1 TO SCHEDULE 13D
Major Shareholding Notification
2020-07-14 English
4
Director's Dealing
2020-07-14 English
4
Director's Dealing
2020-07-14 English
4/A
Director's Dealing
2020-07-11 English
4/A
Director's Dealing
2020-07-11 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) related to a public offering of common stock by Akero Therapeutics, Inc. It includes information about the offering size, underwriting discounts, use of proceeds, risk factors, and company overview. The document is not a financial report, earnings release, or management discussion but rather a registration/prospectus document for a capital raising event. The presence of underwriting details, offering price, and shares offered confirms this is a capital/financing update. The document length (15,000 characters) and content confirm it is the actual prospectus, not just an announcement of a report. Therefore, the correct classification is Capital/Financing Update (CAP).
2020-07-09 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.